Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Notes Payables: 2020-2021

  • Rocket Pharmaceuticals' Notes Payables was N/A to $5.1 million in Q2 2021 from the same period last year, while for Jun 2021 it was $5.1 million, marking a year-over-year change of. This contributed to the annual value of $4.9 million for FY2020, which is N/A change from last year.
  • According to the latest figures from Q2 2021, Rocket Pharmaceuticals' Notes Payables is $5.1 million, which was up 2.33% from $5.0 million recorded in Q1 2021.
  • In the past 5 years, Rocket Pharmaceuticals' Notes Payables registered a high of $5.1 million during Q2 2021, and its lowest value of $4.8 million during Q3 2020.
  • Its 2-year average for Notes Payables is $4.9 million, with a median of $4.9 million in 2020.